MBX Biosciences (MBX) Total Current Liabilities (2023 - 2026)

MBX Biosciences has reported Total Current Liabilities for 4 years, with the latest figure at $14.6 million in Q1 2026.

• Quarterly Total Current Liabilities rose 38.98% year-over-year to $14.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.6 million (up 38.98% YoY) and the FY2025 annual result came in at $15.5 million, up 40.21% from the prior year.
• Total Current Liabilities retreated to $14.6 million in Q1 2026 per MBX's latest filing, from $15.5 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $15.5 million in Q4 2025 and troughed at $3.9 million in Q4 2023.
• A 4-year average of $11.3 million and a median of $11.4 million in 2024 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2024 and 2025: Total Current Liabilities jumped 181.48% in 2024, then advanced 10.46% in 2025.
• Over 4 years, Total Current Liabilities stood at $3.9 million in 2023, then surged by 181.48% to $11.1 million in 2024, then soared by 40.21% to $15.5 million in 2025, then declined by 5.99% to $14.6 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $14.6 million, $15.5 million, and $12.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.